<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897986</url>
  </required_header>
  <id_info>
    <org_study_id>2016-06</org_study_id>
    <nct_id>NCT02897986</nct_id>
  </id_info>
  <brief_title>Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors</brief_title>
  <acronym>PROVIN</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <brief_summary>
    <textblock>
      Cancer remains the first cause of death due to disease in children and adolescents despite&#xD;
      important progress and 70% of the survivors present sequelae. It is therefore mandatory to&#xD;
      generate new and preferably less toxic treatment strategies relying on new anticancer agents,&#xD;
      and/or new combinations or schedules of administered compounds.&#xD;
&#xD;
      Metronomic chemotherapy (MC) consists in administrating low doses of anticancer agents on a&#xD;
      daily/weekly basis. MC has been showed to be a safe and effective way to administer&#xD;
      chemotherapy to obtain anti-cancer effects through anti-angiogenic and pro-imune effects.&#xD;
&#xD;
      Drug repositioning consist in using non-anticancer drug for which anti-cancer properties have&#xD;
      been unveiled. Propranolol is a non selective beta-blocker initially used to treat&#xD;
      hypertension but recently its anticancer properties have been discovered. The place of&#xD;
      Betablockers as anticancer agents is supported by both preclinical and epidemiologic data.&#xD;
      The investigators have showed that the use of betablockers could sensitize breast cancer,&#xD;
      angiosarcoma and neuroblastoma to chemotherapy in vitro and in vivo at least in part via an&#xD;
      anti-angiogenic mechanism. There are currently 12 clinical trials evaluating prospectively&#xD;
      their potential in adults with cancer but none in children so far.&#xD;
&#xD;
      The Objective is to determine the Maximal Tolerated Dose (MTD) of a combination of oral&#xD;
      metronomic vinorelbine and daily oral propranolol. This study is a phase I trial with a&#xD;
      &quot;rolling six&quot; design and a dose escalation with thrice weekly oral vinorelbine only plus&#xD;
      addition of daily oral propranolol after completion of the first cycle. PK analysis of&#xD;
      vinorelbine and propranolol will be performed. Once the recommended dose of the combination&#xD;
      established 4 extension cohorts of 9 patients will be added Potential biomarkers (such as&#xD;
      beta-adrenergic receptors on the tumours, B-tubulin isotypes in the tumour) will also be&#xD;
      evaluated.&#xD;
&#xD;
      This will provide a well tolerated, all oral combination for patients with&#xD;
      refractory/relapsing tumours. This combination could also be then proposed as a maintenance&#xD;
      for instance in patients with rhabdomyosarcoma or neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with grade 3 toxicity</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Pediatric Cancer</condition>
  <arm_group>
    <arm_group_label>patients with refractory/relapsing solid tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination</intervention_name>
    <arm_group_label>patients with refractory/relapsing solid tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignant solid tumour and refractory low&#xD;
             grade gliomas and desmoids tumours.&#xD;
&#xD;
          -  Relapsed or refractory tumours after at least one line of treatment (patients can have&#xD;
             been previously treated with oral or IV vinorelbine with a weekly schedule)&#xD;
&#xD;
          -  Measurable targets&#xD;
&#xD;
          -  Lansky Score &gt; 70 or score OMS &lt; 2.&#xD;
&#xD;
          -  Life expectancy &gt; 6 months.&#xD;
&#xD;
          -  Adequate haematological function: neutrophil count ≥ 1.0 x 109/L, platelet count ≥ 75&#xD;
             x 109/L&#xD;
&#xD;
          -  Creatinine&lt; 1.5X normal value for the age or clearance &gt;70 ml/mn/1.73 m2&#xD;
&#xD;
          -  Liver function: Bilirubin &lt; 3N and ALAT and ASAT &lt; 4 N).&#xD;
&#xD;
          -  Other organ toxicity &lt; Grade 2 according to NCI-CTC version 4.0&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence of a wash out period of:&#xD;
&#xD;
               -  21 days in case of previous chemotherapy or targeted therapy (reduced to 2 weeks&#xD;
                  in case of treatment vincristine or prolonged to 6 weeks in case of treatment&#xD;
                  with nitrosurea agents)&#xD;
&#xD;
               -  6 weeks in case of prior radiotherapy of the target lesions&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 2&#xD;
&#xD;
          -  contra-indication to Propranolol (i.e. asthma, bradycardia, hypotension, decreased SF,&#xD;
             ECG-anomalies)&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urielle Desalbres</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas ANDRE, Professor</last_name>
    <email>nicolas.andre@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas ANDRE, Professor</last_name>
      <email>nicolas.andre@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

